In this article with PharmExec, Beghou Partner Vishal Singal discusses five strategic levers that biotechs can use to tackle this complexity.
- Strategic disease selection
- Early, deep patient engagement
- Maximum launch-curve slope
- Agility-centric organizational design
- Innovative access solutions
These are based on insights from industry leaders at a recent panel discussion he hosted for Beghou, his notes from October’s Cell and Gene Meeting on the Mesa, and his conversation with Rita Johnson-Greene, COO of the Alliance for Regenerative Medicine (ARM).